Benefit of cetuximab addition to a platinum–fluorouracil-based chemotherapy according to KRAS-LCS6 variant in an unselected population of recurrent and/or metastatic head and neck cancers
- 11 Downloads
To evaluate the benefit of cetuximab (Cx) addition to platinum-based and 5-fluorouracil chemotherapy (PFU) in unselected recurrent and/or metastatic head and neck cancer patients (R/MHNC) according to KRAS-LCS6 variant status.
All patients who received at least two PFU ± Cx cycles from 2004 to 2014 were retrospectively included into to two distinct study periods according to Cx implementation: patients treated by PFU alone before 2009 and those treated by PFU + Cx from 2009. Primary objective was to evaluate the progression-free survival (PFS) between the two groups. Secondary objectives were to analyze the overall survival (OS) between the two groups and the prognostic impact of KRAS-LCS6 variant. Factors associated with survival were determined by a Cox multivariate analysis including age, WHO performance status (PS), type of treatment, KRAS-LCS6 variant, Charlson’s score and p16 status.
Overall, 134 patients were included: 59 (44%) in PFU group and 75 (56%) in PFU + Cx group. Baseline characteristics were well balanced including 30% of patients with 2–3 PS. Median PFS was significantly improved in PFU + Cx group compared to PFU group (6.1 vs 4.4 months, respectively, HR 0.68, p = 0.02) and with a trend for better OS. A KRAS-LCS6 variant was found in 27 (25%) of samples without prognostic impact neither in whole population nor according to treatment. In multivariate analysis, addition of Cx to PFU was the only factor significantly associated with a better PFS (p = 0.01, HR 0.6).
Our results suggest that PFU + Cx combination may be effective in unselected population of R/MHNC regardless the KRAS-LCS6 variant status.
KeywordsRecurrent and/or metastatic head and neck cancers Cetuximab Unselected population KRAS-LCS6 Rs61764370 Prognosis
The authors are grateful to Dr. M Bubenheim for his help in statistics and to Dr. T. Ducastelle for his help in collecting histological samples.
This is an academic research. Funding was provided by the Department of Medical Oncology of the Centre Henri Becquerel.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 4.Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer H-R, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116–1127. https://doi.org/10.1056/NEJMoa0802656 CrossRefPubMedGoogle Scholar
- 5.Forastiere AA, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, Kish JA, McClure S, VonFeldt E, Williamson SK (1992) Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 10:1245–1251CrossRefPubMedGoogle Scholar
- 7.Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21–28. https://doi.org/10.1016/S1470-2045(09)70311-0 CrossRefGoogle Scholar
- 8.van der Linden N, Buter J, Pescott CP, Lalisang RI, de Boer JP, de Graeff A, van Herpen CML, Baatenburg de Jong RJ, Uyl-de Groot CA (2016) Treatments and costs for recurrent and/or metastatic squamous cell carcinoma of the head and neck in the Netherlands. Eur Arch Otorhinolaryngol 273:455–464. https://doi.org/10.1007/s00405-015-3495-y CrossRefPubMedGoogle Scholar
- 9.Chung CH, Lee JW, Slebos RJ, Howard JD, Perez J, Kang H, Fertig EJ, Considine M, Gilbert J, Murphy BA, Nallur S, Paranjape T, Jordan RC, Garcia J, Burtness B, Forastiere AA, Weidhaas JB (2014) A 3′-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol 25:2230–2236. https://doi.org/10.1093/annonc/mdu367 CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, Muller R-U, Straka E, Su L, Burki EA, Crowell RE, Patel R, Kulkarni T, Homer R, Zelterman D, Kidd KK, Zhu Y, Christiani DC, Belinsky SA, Slack FJ, Weidhaas JB (2008) A SNP in a let-7 microRNA complementary site in the KRAS 3′UTR increases non-small cell lung cancer risk. Cancer Res 68:8535–8540. https://doi.org/10.1158/0008-5472.CAN-08-2129 CrossRefPubMedPubMedCentralGoogle Scholar
- 11.De Ruyck K, Duprez F, Ferdinande L, Mbah C, Rios-Velazquez E, Hoebers F, Praet M, Deron P, Bonte K, Speel E-J, Libbrecht L, De Neve W, Lambin P, Thierens H (2014) A let-7 microRNA polymorphism in the KRAS 3′-UTR is prognostic in oropharyngeal cancer. Cancer Epidemiol 38:591–598. https://doi.org/10.1016/j.canep.2014.07.008 CrossRefPubMedGoogle Scholar
- 12.Christensen BC, Moyer BJ, Avissar M, Ouellet LG, Plaza SL, McClean MD, Marsit CJ, Kelsey KT (2009) A let-7 microRNA-binding site polymorphism in the KRAS 3′ UTR is associated with reduced survival in oral cancers. Carcinogenesis 30:1003–1007. https://doi.org/10.1093/carcin/bgp099 CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Weidhaas JB, Harris J, Schaue D, Chen AM, Chin R, Axelrod R, El-Naggar AK, Singh AK, Galloway TJ, Raben D, Wang D, Matthiesen C, Avizonis VN, Manon RR, Yumen O, Nguyen-Tan PF, Trotti A, Skinner H, Zhang Q, Ferris RL, Sidransky D, Chung CH (2017) The KRAS-variant and cetuximab response in head and neck squamous cell cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol 3:483–491. https://doi.org/10.1001/jamaoncol.2016.5478 CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Lynggaard CD, Therkildsen MH, Kristensen CA, Specht L (2015) The EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): treatment outcome in a single institution cohort. Acta Oncol 54:1071–1075. https://doi.org/10.3109/0284186X.2014.964308 CrossRefPubMedGoogle Scholar
- 15.de Mello RA, Gerós S, Alves MP, Moreira F, Avezedo I, Dinis J (2014) Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a retrospective study in a single comprehensive European cancer institution. PloS One 9:e86697. https://doi.org/10.1371/journal.pone.0086697 CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Chang PM-H, Hsieh Y-Y, Chen M-H, Tzeng C-H, Chu P-Y, Chang S-Y, Chen P-M, Yang M-H (2010) Cetuximab-based therapy in recurrent/metastatic head and neck squamous cell carcinoma: experience from an area in which betel nut chewing is popular. J Chin Med Assoc 73:292–299. https://doi.org/10.1016/S1726-4901(10)70064-2 CrossRefPubMedGoogle Scholar
- 17.Yoshino T, Hasegawa Y, Takahashi S, Monden N, Homma A, Okami K, Onozawa Y, Fujii M, Taguchi T, Blas B de, Beier F, Tahara M (2013) Platinum-based chemotherapy plus cetuximab for the first-line treatment of Japanese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: results of a phase II trial. Jpn J Clin Oncol 43:524–531. https://doi.org/10.1093/jjco/hyt034 CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Soulières D, Aguilar JL, Chen E, Misiukiewicz K, Ernst S, Lee HJ, Bryant K, He S, Obasaju CK, Chang S-C, Chin S, Adkins D (2016) Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen. BMC Cancer 16:. https://doi.org/10.1186/s12885-016-2064-0
- 19.Herbst RS, Arquette M, Shin DM, Dicke K, Vokes EE, Azarnia N, Hong WK, Kies MS (2005) Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 23:5578–5587. https://doi.org/10.1200/JCO.2005.07.120 CrossRefPubMedGoogle Scholar
- 20.Ying H-Q, Wang F, He B-S, Pan Y-Q, Gao T-Y, Xu Y-Q, Li R, Deng Q-W, Sun H-L, Wang S-K (2014) The involvement of Kras gene 3′-UTR polymorphisms in risk of cancer and influence on patient response to anti-EGFR therapy in metastatic colorectal cancer: a meta-analysis. OncoTargets Ther 7:1487–1496. https://doi.org/10.2147/OTT.S65496 CrossRefGoogle Scholar
- 22.Smits KM, Paranjape T, Nallur S, Wouters KAD, Weijenberg MP, Schouten LJ, van den Brandt PA, Bosman FT, Weidhaas JB, van Engeland M (2011) A let-7 microRNA SNP in the KRAS 3′UTR is prognostic in early-stage colorectal cancer. Clin Cancer Res 17:7723–7731. https://doi.org/10.1158/1078-0432.CCR-11-0990 CrossRefPubMedPubMedCentralGoogle Scholar
- 23.Graziano F, Canestrari E, Loupakis F, Ruzzo A, Galluccio N, Santini D, Rocchi M, Vincenzi B, Salvatore L, Cremolini C, Spoto C, Catalano V, D’Emidio S, Giordani P, Tonini G, Falcone A, Magnani M (2010) Genetic modulation of the Let-7 microRNA binding to KRAS 3′-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan. Pharmacogenom J 10:458–464. https://doi.org/10.1038/tpj.2010.9 CrossRefGoogle Scholar
- 25.Paranjape T, Heneghan H, Lindner R, Keane FK, Hoffman A, Hollestelle A, Dorairaj J, Geyda K, Pelletier C, Nallur S, Martens JW, Hooning MJ, Kerin M, Zelterman D, Zhu Y, Tuck D, Harris L, Miller N, Slack F, Weidhaas J (2011) A 3′-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis. Lancet Oncol 12:377–386. https://doi.org/10.1016/S1470-2045(11)70044-4 CrossRefPubMedPubMedCentralGoogle Scholar